RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 163 filers reported holding RIGEL PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.95 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,639,040 | -16.0% | 1,517,630 | +0.3% | 0.00% | – |
Q2 2023 | $1,952,277 | -2.7% | 1,513,393 | -0.4% | 0.00% | – |
Q1 2023 | $2,005,478 | -11.4% | 1,519,302 | +0.7% | 0.00% | – |
Q4 2022 | $2,263,809 | +18.8% | 1,509,206 | -6.6% | 0.00% | – |
Q3 2022 | $1,906,000 | +2.5% | 1,615,678 | -1.8% | 0.00% | – |
Q2 2022 | $1,859,000 | -63.4% | 1,645,229 | -3.2% | 0.00% | -100.0% |
Q1 2022 | $5,084,000 | +7.8% | 1,700,225 | -4.5% | 0.00% | 0.0% |
Q4 2021 | $4,716,000 | -26.0% | 1,779,455 | +1.3% | 0.00% | 0.0% |
Q3 2021 | $6,377,000 | -18.3% | 1,757,067 | -2.3% | 0.00% | 0.0% |
Q2 2021 | $7,808,000 | +22.1% | 1,799,267 | -3.8% | 0.00% | 0.0% |
Q1 2021 | $6,397,000 | -7.2% | 1,870,621 | -5.0% | 0.00% | 0.0% |
Q4 2020 | $6,892,000 | +44.2% | 1,969,471 | -1.1% | 0.00% | 0.0% |
Q3 2020 | $4,778,000 | +23.6% | 1,990,804 | -5.7% | 0.00% | 0.0% |
Q2 2020 | $3,865,000 | +16.8% | 2,112,101 | -0.4% | 0.00% | 0.0% |
Q1 2020 | $3,309,000 | -27.8% | 2,121,445 | -0.9% | 0.00% | 0.0% |
Q4 2019 | $4,583,000 | +17.4% | 2,141,376 | +2.6% | 0.00% | 0.0% |
Q3 2019 | $3,903,000 | -26.4% | 2,087,556 | +2.7% | 0.00% | 0.0% |
Q2 2019 | $5,305,000 | +2.8% | 2,032,426 | +1.2% | 0.00% | 0.0% |
Q1 2019 | $5,162,000 | +11.6% | 2,008,495 | -0.1% | 0.00% | 0.0% |
Q4 2018 | $4,625,000 | -29.8% | 2,011,142 | -2.0% | 0.00% | -50.0% |
Q3 2018 | $6,589,000 | +16.6% | 2,052,345 | +2.8% | 0.00% | +100.0% |
Q2 2018 | $5,650,000 | -10.2% | 1,996,369 | +12.4% | 0.00% | -50.0% |
Q1 2018 | $6,289,000 | -6.8% | 1,776,443 | +2.1% | 0.00% | 0.0% |
Q4 2017 | $6,749,000 | +78.4% | 1,739,599 | +16.8% | 0.00% | +100.0% |
Q3 2017 | $3,784,000 | -5.5% | 1,489,538 | +1.5% | 0.00% | 0.0% |
Q2 2017 | $4,006,000 | -11.1% | 1,467,524 | +7.8% | 0.00% | 0.0% |
Q1 2017 | $4,506,000 | +71.1% | 1,361,376 | +23.0% | 0.00% | 0.0% |
Q4 2016 | $2,634,000 | -30.6% | 1,106,793 | +7.1% | 0.00% | 0.0% |
Q3 2016 | $3,793,000 | +66.5% | 1,033,198 | +1.2% | 0.00% | 0.0% |
Q2 2016 | $2,278,000 | +14.8% | 1,021,402 | +7.2% | 0.00% | 0.0% |
Q1 2016 | $1,984,000 | -30.6% | 953,240 | +1.1% | 0.00% | 0.0% |
Q4 2015 | $2,858,000 | +27.1% | 943,109 | +3.6% | 0.00% | 0.0% |
Q3 2015 | $2,248,000 | -17.3% | 910,123 | +7.5% | 0.00% | 0.0% |
Q2 2015 | $2,718,000 | -13.6% | 846,539 | -4.0% | 0.00% | 0.0% |
Q1 2015 | $3,147,000 | +54.0% | 881,769 | -2.1% | 0.00% | 0.0% |
Q4 2014 | $2,044,000 | +9.5% | 900,566 | -6.4% | 0.00% | 0.0% |
Q3 2014 | $1,867,000 | -50.7% | 962,387 | -7.7% | 0.00% | 0.0% |
Q2 2014 | $3,786,000 | -12.9% | 1,042,827 | -6.9% | 0.00% | 0.0% |
Q1 2014 | $4,347,000 | +24.8% | 1,120,380 | -8.3% | 0.00% | 0.0% |
Q4 2013 | $3,483,000 | -18.2% | 1,221,970 | +2.7% | 0.00% | -50.0% |
Q3 2013 | $4,260,000 | +4.6% | 1,189,984 | -2.5% | 0.00% | +100.0% |
Q2 2013 | $4,074,000 | – | 1,219,895 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |